Web Results

Alemtuzumab - Wikipedia


Alemtuzumab is a drug used in the treatment of chronic lymphocytic leukemia ( CLL), cutaneous T-cell lymphoma (CTCL) and T-cell lymphoma under the trade ...

Campath.com Consumer Home


Campath, alemtuzumab is a major step forward in the treatment of B-cell chronic lymphocytic leukemia (B-CLL).

Campath (Alemtuzumab): Side Effects, Interactions, Warning ... - RxList


Learn about Campath (Alemtuzumab) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.

Drug Safety and Availability > Alemtuzumab (marketed as Campath ...


Mar 17, 2016 ... This is a summary of the most important information about Campath. For more information, talk to your healthcare professional.

Alemtuzumab Therapy for Multiple Sclerosis


Nov 27, 2012 ... Alemtuzumab is a humanized monoclonal antibody that is administered daily for 5 days, and then no further therapy is required for 12 months.

Alemtuzumab - Drug Information - Chemocare


(ay-lem-TOO-zuh- mab). Trade name: Campath<sup>®</sup>. Chemocare.com uses generic names in all descriptions of drugs. Campath is the trade name for alemtuzumab ...

Alemtuzumab | Multiple Sclerosis Society UK


Sep 6, 2016 ... Latest research and info on Lemtrada (formerly known as alemtuzumab or Campath 1-H), side effects, how it works and when it's likely to be ...

Campath, Lemtrada (alemtuzumab) dosing, indications, interactions ...


Medscape - Chronic lymphocytic leukemia and multiple sclerosis dosing for Campath, Lemtrada (alemtuzumab), frequency-based adverse effects, ...

Alemtuzumab in MS: Disability Reversal Possible - Medscape


Oct 14, 2016 ... New data from the CARE-MS II trial showing that alemtuzumab (Lemtrada, Genzyme) appears to reverse some of the physical disability in ...

Alemtuzumab (MabCampath) | Cancer Research UK


Dec 17, 2015 ... The biological therapy drug alemtuzumab is a treatment for chronic lymphocytic leukaemia. The possible side effects inlcude an increased risk ...

More Info

Relapsing MS Infusion Treatment | LEMTRADA® (alemtuzumab)


LEMTRADA®, because of its risks, is generally for relapsing MS patients who have tried 2 or more MS medicines that didn't work well enough.

FDA Approves Lemtrada™ (alemtuzumab) for Relapsing MS ...


Nov 14, 2014 ... UPDATED December 18, 2014. The U.S. Food and Drug Administration has approved Lemtrada™ (alemtuzumab, Genzyme, a Sanofi ...

Alemtuzumab therapy for multiple sclerosis. - NCBI


Alemtuzumab is a humanized monoclonal antibody that is administered daily for 5 days, and then no further therapy is required for 12 months. It causes rapid ...